Farmmi released FY2025 Q1 earnings on August 1, 2025, EST with actual revenue of USD 8.072 M and EPS of USD -0.0204

Brief Summary

Farmmi reported its Q1 2025 financial results with a revenue of 8.07 million USD and an EPS of -0.0204 USD, indicating a challenging quarter.

Impact of The News

Company Performance Analysis

• Earnings Per Share (EPS): Farmmi reported an EPS of -0.0204 USD, highlighting a net loss for the quarter. This figure demonstrates financial difficulties when considering the company’s profitability.
• Revenue: The revenue for the quarter stood at 8.07 million USD. Without a benchmark from market expectations or peers, it’s difficult to ascertain its performance relative to expectations.

Industry & Peer Comparison

• Peer Performance Context: Within the same reporting period, companies like APLD and IRadimed Corporation reported significant revenue growth. For instance, APLD’s revenue increased by 41% in Q4 2025, and IRadimed’s Q2 2025 revenue was 20.41 million USD, which exceeded expectations LB filings. Farmmi’s performance, with a loss in EPS, contrasts with these peers, indicating it may be underperforming in its sector.

Impact and Future Outlook

• Business Status: The negative EPS and the revenue figures suggest that Farmmi is struggling with profitability and possibly market competitiveness. This can affect investor confidence, leading to potential downward pressure on its stock price.
• Future Development Trends: Given the current financial standing, Farmmi may need to focus on improving operational efficiencies and exploring new revenue streams to overcome its current challenges. Cost management strategies and potential partnerships or innovations could help pivot its business trajectory towards a more positive future outlook.